HomeCompareCCOEF vs ABBV

CCOEF vs ABBV: Dividend Comparison 2026

CCOEF yields 1.21% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CCOEF wins by $8.76M in total portfolio value· pulled ahead in Year 5
10 years
CCOEF
CCOEF
● Live price
1.21%
Share price
$22.28
Annual div
$0.27
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.87M
Annual income
$7,653,357.56
Full CCOEF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — CCOEF vs ABBV

📍 CCOEF pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCCOEFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CCOEF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CCOEF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CCOEF
Annual income on $10K today (after 15% tax)
$103.00/yr
After 10yr DRIP, annual income (after tax)
$6,505,353.93/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, CCOEF beats the other by $6,483,487.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CCOEF + ABBV for your $10,000?

CCOEF: 50%ABBV: 50%
100% ABBV50/50100% CCOEF
Portfolio after 10yr
$4.49M
Annual income
$3,839,541.64/yr
Blended yield
85.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CCOEF
Analyst Ratings
1
Sell
Consensus: Sell
Altman Z
25.5
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CCOEF buys
0
ABBV buys
0
No recent congressional trades found for CCOEF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCCOEFABBV
Forward yield1.21%3.12%
Annual dividend / share$0.27$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$8.87M$104.7K
Annual income after 10y$7,653,357.56$25,725.73
Total dividends collected$8.75M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusSellBuy

Year-by-year: CCOEF vs ABBV ($10,000, DRIP)

YearCCOEF PortfolioCCOEF Income/yrABBV PortfolioABBV Income/yrGap
1$10,942$242.35$11,559$438.51$617.00ABBV
2$12,204$495.67$13,494$640.86$1.3KABBV
3$14,092$1,033.32$15,951$945.97$1.9KABBV
4$17,308$2,230.17$19,152$1,413.89$1.8KABBV
5← crossover$23,640$5,120.06$23,443$2,146.38+$197.00CCOEF
6$38,366$13,071.17$29,391$3,321.96+$9.0KCCOEF
7$80,703$39,651.60$37,948$5,265.87+$42.8KCCOEF
8$242,254$155,902.32$50,795$8,596.74+$191.5KCCOEF
9$1,133,957$874,744.36$71,034$14,549.41+$1.06MCCOEF
10$8,866,691$7,653,357.56$104,715$25,725.73+$8.76MCCOEF

CCOEF vs ABBV: Complete Analysis 2026

CCOEFStock

Capcom Co., Ltd. plans, develops, manufactures, sells, and distributes home video games, online games, mobile games, and arcade games in Japan and internationally. It operates through Digital Contents, Arcade Operations, Amusement Equipments, and Other Businesses segments. The Digital Contents segment develops and sells packaged and digital game content for consumer home video game platforms, as well as mobile content and PC online games. The Arcade Operations segment operates Plaza Capcom amusement facilities primarily in commercial complexes, as well as hosts various events. The Amusement Equipments segment is involved in the development, manufacture, and sale of frames and LCD devices for gaming machines, as well as software. The Other Businesses segment publishes walkthrough and strategy guides, as well as game art books; licenses movies, animated television programs, music CDs, and merchandise; and focuses on the esports business. It also manages amusement arcades. Capcom Co., Ltd. was incorporated in 1979 and is headquartered in Osaka, Japan.

Full CCOEF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CCOEF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CCOEF vs SCHDCCOEF vs JEPICCOEF vs OCCOEF vs KOCCOEF vs MAINCCOEF vs JNJCCOEF vs MRKCCOEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.